Levetiracetam

Levetiracetam is used to control seizure activity in various epilepsy syndromes.

• Partial seizures: Reduces frequency of focal onset seizures, improving seizure control.
• Generalized tonic-clonic seizures: Decreases occurrence of bilateral convulsive seizures in patients with epilepsy.
• Myoclonic seizures: Helps prevent sudden muscle jerks associated with myoclonic epilepsy.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent vesicle exocytosis, stabilizing neuronal membranes and reducing hyper‑excitability. By decreasing the release of excitatory neurotransmitters, the drug lowers the likelihood of synchronized neuronal firing that underlies seizure generation. The precise downstream pathways remain under investigation, but the overall effect is a net anticonvulsant activity without significant interaction with ion channels or G‑protein coupled receptors.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Drowsiness: Feeling unusually sleepy or fatigued.
• Dizziness: Light‑headed sensation or loss of balance.
• Headache: Mild to moderate cranial pain.
• Irritability: Mood changes including increased agitation.
• Nausea: Stomach upset or urge to vomit.

Serious or Rare Side Effects

• Severe allergic reaction: Rash, swelling, or breathing difficulty.
• Mood or behavior changes: Depression, suicidal thoughts, or aggression.
• Blood disorders: Unusual bruising, bleeding, or low blood cell counts.
• Liver dysfunction: Jaundice or elevated liver enzymes.
• Multiorgan hypersensitivity: Rare systemic reaction requiring immediate medical attention.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: Adjust dose in patients with impaired kidney function.
• Psychiatric history: Monitor for mood swings, depression, or suicidal ideation.
• Pregnancy: Use only if potential benefit justifies potential risk, as safety data are limited.
• Concomitant CNS depressants: Observe for additive sedation or respiratory depression.
• Driving and machinery: Caution patients about possible drowsiness affecting alertness.
• Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Carbamazepine: May reduce levetiracetam plasma levels, decreasing effectiveness.
• Phenobarbital: Can lower levetiracetam concentrations, requiring close monitoring.

Moderate Interactions (Monitor Closely)

• Alcohol: Combined use may enhance central nervous system depression.
• Opioids: May increase risk of sedation and respiratory depression.
• Other antiepileptics (e.g., valproate): Potential additive side effects, monitor patient response.